Drugs / BPI-9016
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02929290 | Mar 2017 → Nov 2024 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02478866 | Aug 2015 → Jun 2017 | cancer | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-9016 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545236 ↗ |
| Known as | BPI-9016M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02929290 ↗ |
| Action | Inhibit | “BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases.” PMID 31948451 ↗ Jan 2020 |
| Modality | Small molecule | “BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases.” PMID 31948451 ↗ Jan 2020 |
| Route | Oral | “BPI-9016M administered orally once daily (QD)” NCT02478866 ↗ |
| Target | AXL | “BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases.” PMID 31948451 ↗ Jan 2020 |
| Target | MET | “BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases.” PMID 31948451 ↗ Jan 2020 |